{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-012903","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.151818+00:00","generated_at":"2026-06-12T13:02:51.462033+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coherus Q2 net revenue $58.7M (+81% QoQ); CIMERLI sales quadruple to $26.7M","bullets":["Net revenue $58.7M, up 81% from prior quarter; UDENYCA $31.7M, CIMERLI $26.7M.","Net loss $42.9M ($0.49 diluted EPS); non-GAAP net loss $32.8M ($0.38).","Launched UDENYCA autoinjector in May, YUSIMRY (Humira biosimilar) in July.","Planned merger with Surface Oncology expected to close after Sep 7 shareholder meeting.","FDA inspections for toripalimab ongoing; potential approval and launch H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-012903","json":"https://secwatch.observer/filing/0001558370-23-012903.json","markdown":"https://secwatch.observer/filing/0001558370-23-012903.md","text":"https://secwatch.observer/filing/0001558370-23-012903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/0001558370-23-012903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/chrs-20230802x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:02:51.462033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f80eebdf367bc39871f6b9565bd72c314b01653","claim":"Coherus Oncology, Inc. reported the second quarter ended June 30, 2023 results: revenue $58.7 million.","evidence_excerpt":"Net revenue was $58.7 million during the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837023012903/0001558370-23-012903-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$58.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}